VERTEX PHARMACEUTICALS INC / MA Form 8-K July 02, 2004

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 24, 2004

VERTEX PHARMACEUTICALS INCORPORATED

(Exact name of registrant as specified in its charter)

MASSACHUSETTS 000-19319 04-3039129

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.

130 Waverly Street

Cambridge, Massachusetts 02139


(Address of principal executive offices) (Zip Code)

MASSACHUSETTS 1

(617) 444-6100

Registrant s telephone number, including area code:

MASSACHUSETTS 2



MASSACHUSETTS 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS INCORPORATED

(Registrant)

Date: July 1, 2004

/s/ Ian F. Smith Ian F. Smith

Senior Vice President and Chief Financial Officer

SIGNATURES 4

EXHIBIT INDEX

The following exhibits are filed as part of this current report on Form 8-K:

Exhibit No.	Description
99.1	Press Release of Vertex Pharmaceuticals Incorporated, dated May 24, 2004.
99.2	Research, Development and Commercialization Agreement between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated dated May 24, 2004 (with certain confidential information deleted).
99.3	Press Release of Vertex Pharmaceuticals Incorporated, dated June 22, 2004.
99.4	Exclusive Research Collaboration, License and Commercialization Agreement by and between the Registrant and Merck & Co., Inc., dated June 22, 2004 (with certain confidential information deleted).

SIGNATURES 5